In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.

In this webinar, we will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:

"We select patients on biology, but we lose them on circumstance."

That single sentence is the reason Luvida’s hosting a dinner.

We obsess over first patient in. But the metric that actually decides whether a trial succeeds is last patient in, and too often we lose people not because the science failed, but because the trial was never designed around the reality of their lives.

Luvida is a London-based company that integrates social determinants of health data to predict and mitigate clinical trial risk.

Fierce Biotech at London Life Sciences Week is a one-day event convening 200-250 leaders from across 
the global biopharma and investment ecosystem. The event centers on scientific innovation, drug development  and dealmaking, creating a platform for life science executives, investors and business development leaders to explore cutting-edge science and strategic partnerships.

Interactive Networking Panel, live in Hammersmith London, 15 September, 1730-1930 GMT